158 related articles for article (PubMed ID: 23108949)
1. A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck.
Abdul Razak AR; Soulières D; Laurie SA; Hotte SJ; Singh S; Winquist E; Chia S; Le Tourneau C; Nguyen-Tan PF; Chen EX; Chan KK; Wang T; Giri N; Mormont C; Quinn S; Siu LL
Ann Oncol; 2013 Mar; 24(3):761-9. PubMed ID: 23108949
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001).
Prawira A; Brana-Garcia I; Spreafico A; Hope A; Waldron J; Razak AR; Chen EX; Jang R; O'Sullivan B; Giuliani M; Bayley A; Cho J; Wang L; Perez-Ordonez B; Weinreb I; Siu LL; Hansen AR
Invest New Drugs; 2016 Oct; 34(5):575-83. PubMed ID: 27289242
[TBL] [Abstract][Full Text] [Related]
3. Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.
Kim HS; Kwon HJ; Jung I; Yun MR; Ahn MJ; Kang BW; Sun JM; Kim SB; Yoon DH; Park KU; Lee SH; Koh YW; Kim SH; Choi EC; Koo DH; Sohn JH; Kim B; Kwon NJ; Yun HJ; Lee MG; Lee JH; Kim TM; Kim HR; Kim JH; Paik S; Cho BC
Clin Cancer Res; 2015 Feb; 21(3):544-52. PubMed ID: 25424851
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic assessment of dacomitinib (pan-HER tyrosine kinase inhibitor) in patients with locally advanced head and neck squamous cell carcinoma (LA SCCHN) following administration through a gastrostomy feeding tube (GT).
Chiu JW; Chan K; Chen EX; Siu LL; Abdul Razak AR
Invest New Drugs; 2015 Aug; 33(4):895-900. PubMed ID: 25937431
[TBL] [Abstract][Full Text] [Related]
5. Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma.
Kim HS; Kim SM; Kim H; Pyo KH; Sun JM; Ahn MJ; Park K; Keam B; Kwon NJ; Yun HJ; Kim HG; Chung IJ; Lee JS; Lee KH; Kim DJ; Lee CG; Hur J; Chung H; Park JC; Shin SK; Lee SK; Kim HR; Moon YW; Lee YC; Kim JH; Paik S; Cho BC
Oncotarget; 2015 Dec; 6(42):44971-84. PubMed ID: 26462025
[TBL] [Abstract][Full Text] [Related]
6. First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study.
Necchi A; Lo Vullo S; Perrone F; Raggi D; Giannatempo P; Calareso G; Nicolai N; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Togliardi E; Colecchia M; Busico A; Gloghini A; Testi A; Mariani L; Salvioni R
BJU Int; 2018 Mar; 121(3):348-356. PubMed ID: 28921872
[TBL] [Abstract][Full Text] [Related]
7. Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-Based Therapy.
Machiels JP; Van Maanen A; Vandenbulcke JM; Filleul B; Seront E; Henry S; D'Hondt L; Lonchay C; Holbrechts S; Boegner P; Brohee D; Dequanter D; Louviaux I; Sautois B; Whenham N; Berchem G; Vanderschueren B; Fontaine C; Schmitz S; Gillain A; Schoonjans J; Rottey S
Oncologist; 2016 Dec; 21(12):1416-e17. PubMed ID: 27903924
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Seiwert T; Sarantopoulos J; Kallender H; McCallum S; Keer HN; Blumenschein G
Invest New Drugs; 2013 Apr; 31(2):417-24. PubMed ID: 22918720
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.
Schöffski P; Catimel G; Planting AS; Droz JP; Verweij J; Schrijvers D; Gras L; Schrijvers A; Wanders J; Hanauske AR
Ann Oncol; 1999 Jan; 10(1):119-22. PubMed ID: 10076732
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck.
Vermorken JB; Licitra L; Stöhlmacher-Williams J; Dietz A; Lopez-Picazo JM; Hamid O; Hossain AM; Chang SC; Gauler TC
Eur J Cancer; 2013 Sep; 49(13):2877-83. PubMed ID: 23726971
[TBL] [Abstract][Full Text] [Related]
12. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.
Soulières D; Faivre S; Mesía R; Remenár É; Li SH; Karpenko A; Dechaphunkul A; Ochsenreither S; Kiss LA; Lin JC; Nagarkar R; Tamás L; Kim SB; Erfán J; Alyasova A; Kasper S; Barone C; Turri S; Chakravartty A; Chol M; Aimone P; Hirawat S; Licitra L
Lancet Oncol; 2017 Mar; 18(3):323-335. PubMed ID: 28131786
[TBL] [Abstract][Full Text] [Related]
13. A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer.
Fury MG; Sherman E; Lisa D; Agarwal N; Algazy K; Brockstein B; Langer C; Lim D; Mehra R; Rajan SK; Korte S; Lipson B; Yunus F; Tanvetyanon T; Smith-Marrone S; Ng K; Xiao H; Haque S; Pfister DG
J Natl Compr Canc Netw; 2012 Nov; 10(11):1391-8. PubMed ID: 23138167
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck.
de Souza JA; Davis DW; Zhang Y; Khattri A; Seiwert TY; Aktolga S; Wong SJ; Kozloff MF; Nattam S; Lingen MW; Kunnavakkam R; Stenson KM; Blair EA; Bozeman J; Dancey JE; Vokes EE; Cohen EE
Clin Cancer Res; 2012 Apr; 18(8):2336-43. PubMed ID: 22371453
[TBL] [Abstract][Full Text] [Related]
15. PRISM: Phase 2 trial with panitumumab monotherapy as second-line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Rischin D; Spigel DR; Adkins D; Wein R; Arnold S; Singhal N; Lee O; Murugappan S
Head Neck; 2016 Apr; 38 Suppl 1():E1756-61. PubMed ID: 26681429
[TBL] [Abstract][Full Text] [Related]
16. Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.
Jimeno A; Machiels JP; Wirth L; Specenier P; Seiwert TY; Mardjuadi F; Wang X; Kapp AV; Royer-Joo S; Penuel E; McCall B; Pirzkall A; Clement PM
Cancer; 2016 Dec; 122(24):3803-3811. PubMed ID: 27525588
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer.
Argiris A; Cohen E; Karrison T; Esparaz B; Mauer A; Ansari R; Wong S; Lu Y; Pins M; Dancey J; Vokes E
Cancer Biol Ther; 2006 Jul; 5(7):766-70. PubMed ID: 16760642
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.
Cohen EE; Rosen F; Stadler WM; Recant W; Stenson K; Huo D; Vokes EE
J Clin Oncol; 2003 May; 21(10):1980-7. PubMed ID: 12743152
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma.
Geiger JL; Bauman JE; Gibson MK; Gooding WE; Varadarajan P; Kotsakis A; Martin D; Gutkind JS; Hedberg ML; Grandis JR; Argiris A
Head Neck; 2016 Dec; 38(12):1759-1764. PubMed ID: 27232378
[TBL] [Abstract][Full Text] [Related]
20. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
Machiels JP; Haddad RI; Fayette J; Licitra LF; Tahara M; Vermorken JB; Clement PM; Gauler T; Cupissol D; Grau JJ; Guigay J; Caponigro F; de Castro G; de Souza Viana L; Keilholz U; Del Campo JM; Cong XJ; Ehrnrooth E; Cohen EE;
Lancet Oncol; 2015 May; 16(5):583-94. PubMed ID: 25892145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
